Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
Zoë Y G J van LieropAlyssa A TooropWouter Jc van BallegoijTom Bg Olde DubbelinkEva Mm StrijbisBrigit A de JongBob W van OostenBastiaan MoraalCharlotte E TeunissenBernard Mj UitdehaagJoep KillesteinZoé LE van KempenPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previous dose, repeated 4-weekly). Median interval until re-dosing or last B-cell count was 34 [30-38] weeks. No clinical relapses were reported and a minority of patients showed Expanded Disability Status Scale (EDSS) progression. Monthly serum neurofilament light levels remained stable during extended intervals. Two (1.9%) of 107 patients with a follow-up magnetic resonance imaging (MRI) scan showed radiological disease activity. Personalized dosing of ocrelizumab could significantly extend intervals with low short-term disease activity incidence, encouraging future research on long-term safety and efficacy.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- magnetic resonance imaging
- ankylosing spondylitis
- juvenile idiopathic arthritis
- end stage renal disease
- computed tomography
- induced apoptosis
- ejection fraction
- multiple sclerosis
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- peripheral blood
- oxidative stress
- cell death
- cell cycle arrest
- gestational age
- patient reported outcomes
- cerebrospinal fluid
- cell proliferation
- endoplasmic reticulum stress
- current status
- nk cells